Three months of dual antiplatelet therapy after coronary revascularisation: sufficient protection with lower bleeding risk?
A randomised, multicentre, double blind trial across thirteen hospitals in China comparing ticagrelor plus aspirin dual antiplatelet therapy for three versus 12 months in patients undergoing coronary artery bypass grafting with at least one saphenous vein graft.